These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 34503215)

  • 1. Niraparib Suppresses Cholangiocarcinoma Tumor Growth by Inducing Oxidative and Replication Stress.
    Bezrookove V; Patino JM; Nosrati M; Desprez PY; McAllister S; Soroceanu L; Baron A; Osorio R; Kashani-Sabet M; Dar AA
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
    Li H; Tu J; Zhao Z; Chen L; Qu Y; Li H; Yao H; Wang X; Lee DF; Shen J; Wen L; Huang G; Xie X
    Theranostics; 2020; 10(21):9477-9494. PubMed ID: 32863940
    [No Abstract]   [Full Text] [Related]  

  • 3. Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9.
    Saqub H; Proetsch-Gugerbauer H; Bezrookove V; Nosrati M; Vaquero EM; de Semir D; Ice RJ; McAllister S; Soroceanu L; Kashani-Sabet M; Osorio R; Dar AA
    Sci Rep; 2020 Oct; 10(1):18489. PubMed ID: 33116269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PARP inhibitor synthetic lethality in ATM biallelic mutant cancer cell lines is associated with BRCA1/2 and RAD51 downregulation.
    Muvaffak A; Coleman KG
    Front Oncol; 2024; 14():1380633. PubMed ID: 38807759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.
    Bahar E; Kim JY; Kim DC; Kim HS; Yoon H
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models.
    Sambade MJ; Van Swearingen AED; McClure MB; Deal AM; Santos C; Sun K; Wang J; Mikule K; Anders CK
    Neurooncol Adv; 2019; 1(1):vdz005. PubMed ID: 32642648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.
    Chornenkyy Y; Agnihotri S; Yu M; Buczkowicz P; Rakopoulos P; Golbourn B; Garzia L; Siddaway R; Leung S; Rutka JT; Taylor MD; Dirks PB; Hawkins C
    Mol Cancer Ther; 2015 Nov; 14(11):2560-8. PubMed ID: 26351319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Niraparib-induced STAT3 inhibition increases its antitumor effects.
    Zhao Q; Kohut A; Li YJ; Martincuks A; Austria T; Zhang C; Santiago NL; Borrero RM; Phan XT; Melstrom L; Rodriguez-Rodriguez L; Yu H
    Front Oncol; 2022; 12():966492. PubMed ID: 36324587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation.
    Serra-Camprubí Q; Verdaguer H; Oliveros W; Lupión-Garcia N; Llop-Guevara A; Molina C; Vila-Casadesús M; Turpin A; Neuzillet C; Frigola J; Querol J; Yáñez-Bartolomé M; Castet F; Fabregat-Franco C; Escudero-Iriarte C; Escorihuela M; Arenas EJ; Bernadó-Morales C; Haro N; Giles FJ; Pozo ÓJ; Miquel JM; Nuciforo PG; Vivancos A; Melé M; Serra V; Arribas J; Tabernero J; Peiró S; Macarulla T; Tian TV
    Clin Cancer Res; 2023 Jan; 29(2):432-445. PubMed ID: 36374558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
    Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
    Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer.
    Vitiello PP; Martini G; Mele L; Giunta EF; De Falco V; Ciardiello D; Belli V; Cardone C; Matrone N; Poliero L; Tirino V; Napolitano S; Della Corte C; Selvaggi F; Papaccio G; Troiani T; Morgillo F; Desiderio V; Ciardiello F; Martinelli E
    J Exp Clin Cancer Res; 2021 Jan; 40(1):15. PubMed ID: 33407715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Emerging Role of Poly (ADP-Ribose) Polymerase Inhibitors as Effective Therapeutic Agents in Renal Cell Carcinoma.
    Pletcher JP; Bhattacharjee S; Doan JP; Wynn R; Sindhwani P; Nadiminty N; Petros FG
    Front Oncol; 2021; 11():681441. PubMed ID: 34307148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term starvation synergistically enhances cytotoxicity of Niraparib via Akt/mTOR signaling pathway in ovarian cancer therapy.
    Zhi W; Li S; Wan Y; Wu F; Hong L
    Cancer Cell Int; 2022 Jan; 22(1):18. PubMed ID: 35016681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
    Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
    J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Genomic Profiling-Guided Niraparib Treatment of Triple-Negative Breast Cancer in a Patient With Extensive Brain Metastasis: Case Report and Literature Review.
    Lam TC
    J Immunother Precis Oncol; 2021 Feb; 4(1):16-20. PubMed ID: 35664827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
    Ricci AD; Rizzo A; Bonucci C; Tober N; Palloni A; Mollica V; Maggio I; Deserti M; Tavolari S; Brandi G
    Medicines (Basel); 2020 Aug; 7(9):. PubMed ID: 32878011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valproate augments Niraparib killing of tumor cells.
    Booth L; Roberts JL; Rais R; Poklepovic A; Dent P
    Cancer Biol Ther; 2018; 19(9):797-808. PubMed ID: 29923797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The PARP1 Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with Temozolomide for Antimyeloma Effects.
    Shen HY; Tang HL; Zheng YH; Feng J; Dong BX; Chen XQ
    J Oncol; 2022; 2022():2800488. PubMed ID: 35422863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Niraparib in ovarian cancer: results to date and clinical potential.
    Caruso D; Papa A; Tomao S; Vici P; Panici PB; Tomao F
    Ther Adv Med Oncol; 2017 Sep; 9(9):579-588. PubMed ID: 29081841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study.
    Golan T; Raitses-Gurevich M; Kelley RK; Bocobo AG; Borgida A; Shroff RT; Holter S; Gallinger S; Ahn DH; Aderka D; Apurva J; Bekaii-Saab T; Friedman E; Javle M
    Oncologist; 2017 Jul; 22(7):804-810. PubMed ID: 28487467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.